Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
David A Boothman; Sandeep Burma; Amyn A Habib; Jack M Raisanen; Yang Xie; Hao Tang)
Neoplasia (United States). 2013;15(8):888-897.Abstract
Tumor necrosis factor receptor 1 (TNFR1)-associated death domain protein (TRADD) is an important adaptor in TNFR1 signaling and has an essential role in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and survival signaling. Increased expression of TRADD is sufficient to activate NF-κB. Recent studies have highlighted the importance of NF-κB activation as a key pathogenic mechanism in glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.We examined the expression of TRADD by immunohistochemistry (IHC) and find that TRADD is commonly expressed at high levels in GBM and is detected in both cytoplasmic and nuclear distribution. Cytoplasmic IHC TRADD scoring is significantly associated with worse progression-free survival (PFS) both in univariate and multivariate analysis but is not associated with overall survival (n = 43 GBMs). PFS is a marker for responsiveness to treatment. We propose that TRADD-mediated NF-κB activation confers chemoresistance and thus a worse PFS in GBM. Consistent with the effect on PFS, silencing TRADD in glioma cells results in decreased NF-κB activity, decreased proliferation of cells, and increased sensitivity to temozolomide. TRADD expression is common in glioma-initiating cells. Importantly, silencing TRADD in GBM-initiating stem cell cultures results in decreased viability of stem cells, suggesting that TRADD may be required for maintenance of GBM stem cell populations. Thus, our study suggests that increased expression of cytoplasmic TRADD is both an important biomarker and a key driver of NF-κB activation in GBM and supports an oncogenic role for TRADD in GBM. © 2013 Neoplasia Press, Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Tie Fu Liu; Philip D. Hall; Kimberley A. Cohen; Mark C. Willingham; Jiaozhong Cai; Andrew Thorburn; Arthur E. FrankelClinical Cancer Research. 2005;11(1):329-334.
Edward Pan; Daohai Yu; Binglin Yue; Lisa Potthast; Sajeel Chowdhary; Pamela Smith; Marc ChamberlainJournal of Neuro-Oncology. 2012;110(1):111-118.
Shenghui He; Toshihide Iwashita; Johanna Buchstaller; Anna V. Molofsky; Dafydd Thomas; Sean J. MorrisonDevelopmental Biology. 2009;328(2):257-272.
Appears in this Document